3-D Matrix, Ltd.
Completion of Malignant Pleural Mesothelioma Clinical Trial｜June 2026
The company has completed a Phase I investigator-initiated clinical trial of 'MIRX002' targeting malignant pleural mesothelioma, achieving safety and primary endpoints. Future plans include advancing overseas clinical development.
Key Figures
- Clinical trial completion: Unknown
- Safety and tolerability assessment: Primary endpoints achieved
- Overseas clinical development: Ongoing
AI要約
Performance Overview
This document reports that the company has completed a Phase I investigator-initiated clinical trial of 'MIRX002' targeting malignant pleural mesothelioma, achieving safety and primary endpoints. The trial confirmed safety in both single and repeated dosing tests, with no adverse effects observed, demonstrating safe administration up to three times. This progress advances preparations for overseas clinical development and represents a significant milestone for future business expansion.
Future Outlook and Corporate Activities
The company will continue development in collaboration with PURMX Corporation. The trial results accelerate overseas clinical development for this drug, which has received orphan drug designation in the United States. The direct impact on future business development and revenue remains unknown at this stage. This progress is also positioned as an important milestone in the company's medium-term management plan.
Three-Dee Matrix Inc.
Company overview · Stock price · Financial data · All IR
